Nykode Therapeutics As (VACBF) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Nykode Therapeutics Asa.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.892 -- 00:00:06.180 Greetings, and welcome to the NICO Therapeutics Q3 2025 Financial 00:00:06.180 -- 00:00:10.627 Results Conference Calling Webcast. At this time, all participants are in a listen-only 00:00:10.627 -- 00:00:14.513 mode. A question-and-answer session will follow the formal presentation. 00:00:14.513 -- 00:00:19.161 You may ask a question any time by typing it into the Ask a Question feature on your 00:00:19.161 -- 00:00:23.207 screen. As a reminder, this conference is being recorded. 00:00:23.207 -- 00:00:26.793 It's now my pleasure to turn the call over to CEO Michael Ansig. 00:00:26.793 -- 00:00:29.292 Please go ahead, sir. 00:00:29.292 -- 00:00:33.278 Thank you very much, Kevin. Also, from my side, a very warm welcome to all participants 00:00:33.278 -- 00:00:36.322 at today's Q3 report. 00:00:36.322 -- 00:00:38.986 Just to remind everybody of our forward-looking statements. 00:00:38.986 -- 00:00:43.993 Assuming you're familiar with such statements, we will move ahead. 00:00:43.993 -- 00:00:49.441 As usual, it's my pleasure to have next to me here André Fredriksen, our Chief Scientific 00:00:49.441 -- 00:00:54.428 Officer and Head of Business Development, as well as co-founder, and Gorgon, our Chief 00:00:54.428 -- 00:00:56.909 Financial Officer. 00:00:57.642 -- 00:01:02.872 Just a quick recap on our company strategy, which we 00:01:02.872 -- 00:01:05.797 announced in Q3 00:01:05.797 -- 00:01:11.729 this year, which really demonstrates our focus on our three core assets of ISUBA, 00:01:11.729 -- 00:01:14.033 formerly known as VB1016, 00:01:14.033 -- 00:01:18.381 which is our lead asset, and we're taking it into a randomized control cloud in Phase 00:01:18.381 -- 00:01:23.558 2, and first line hit the neck. Secondly, we retain NEO, ...